Among all these biomarkers, PD-L1 expression, microsatellite instability (MSI), tumor mutation burden (TMB), and mismatch repair deficiency (dMMR) have been well-established to determine whether patients can benefit from ICIs 417, 418. Here, CD274 is linked to neoplasm.